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Abstract
Background Prevention of secondary stroke following initial ictus is an important focus of after-stroke care. Blood pres-
sure (BP) is a key risk factor, so usual care following stroke or transient ischaemic attack includes regular BP checks and 
monitoring of anti-hypertensive medication. This is traditionally carried out in primary care, but the evidence supporting 
self-monitoring and self-guided management of BP in the general population with hypertension is growing.
Objective Our objective was to estimate the cost effectiveness of treatment as usual (TAU) versus (1) self-monitoring of BP 
(S-MON) and (2) self-monitoring and guided self-management of anti-hypertensive medication (S-MAN).
Methods This was a within-trial economic evaluation of a randomised controlled trial estimating the incremental cost per 
1 mmHg BP reduction and per quality-adjusted life-year (QALY) gained over a 6-month time horizon from the perspective 
of the UK National Health Service (NHS).
Results Data were evaluable for 140 participants. Costs per patient were £473, £853 and £1035; mean reduction in systolic 
BP (SBP) was 3.6, 6.7 and 6.1 mmHg, and QALYs accrued were 0.427, 0.422 and 0.423 for TAU, S-MON and S-MAN, 
respectively. No statistically significant differences in incremental costs or outcomes were detected. On average, S-MAN 
was dominated or extended dominated. The incremental cost per 1 mmHg BP reduction from S-MON versus TAU was £137.
Conclusion On average, S-MAN is an inefficient intervention. S-MON may be cost effective, depending on the willingness 
to pay for a 1 mmHg BP reduction, although it yielded fewer QALYs over the within-trial time horizon. Decision modelling 
is required to explore the longer-term costs and outcomes.
1 Introduction
Prevention of stroke recurrence following initial stroke or 
transient ischaemic attack (TIA) is an important focus for 
secondary prevention, the risk being substantially reduced 
by good blood pressure (BP) control [1–3]. Usual care fol-
lowing stroke and TIA therefore includes regular BP checks 
and monitoring of anti-hypertensive medications, which are 
usually carried out in primary care.
In recent years, evidence supporting the use of self-
monitoring and guided management of BP in the general 
population with high BP has been growing [4, 5]. Several 
studies have reported benefits in terms of BP reductions 
and improved control, and this approach therefore offers a 
potential opportunity to not only translate these benefits to 
patients with a history of stroke or TIA but also to reduce the 
primary care burden associated with after-stroke care. Since 
no consensus yet exists regarding whether specific sub-
groups (such as those with a history of stroke/TIA) benefit 
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from this strategy, or whether guided self-management in 
conjunction with self-monitoring offers a superior approach 
to self-monitoring alone [6], it remains important to evaluate 
these strategies in specific subpopulations of interest.
TEST-BP (Trial of the Effectiveness of Self-monitoring/
Treatment of BP after stroke; ClinicalTrials.gov reference 
NCT02947490) was a randomised controlled trial that 
assessed the benefits in terms of BP reduction and reaching 
target levels using these approaches in patients following 
stroke or TIA. The trial reported small and statistically non-
significant improvements in systolic BP (SBP) over 6 months 
in patients using both self-monitoring of BP and self-monitor-
ing plus guided management of their anti-hypertensive medi-
cations compared with usual care [7]. Although BP reduction 
and control rates were not statistically significantly different 
between the interventions, these results demonstrated that this 
approach to after-stroke BP care was both safe and well-tol-
erated (only 2% of patients receiving the intervention did not 
comply with the BP measurement protocol) among patients 
with stroke or TIA. Self-monitoring and guided self-manage-
ment were associated with significantly greater increases in 
anti-hypertensive drug use than was usual treatment.
In this study, we estimated the within-trial cost effec-
tiveness of self-monitoring and self-management of BP in 
patients with a history of stroke or TIA. We used patient 
data from TEST-BP to combine information about the SBP 
reduction benefits and the associated costs to assess the 
short-term cost effectiveness of these interventions.
2  Methods
2.1  Clinical Study
Full details of the results of TEST-BP have been published 
elsewhere [7]. In brief, 171 community-dwelling adults in 
England with a recent mild or moderate stroke or TIA requir-
ing anti-hypertensive treatment to prevent recurrence were 
randomised into the three arms of the trial between Decem-
ber 2012 and March 2016, of whom 154 were included in 
the final outcomes analysis: (1) treatment as usual (TAU, 
n = 52), (2) self-monitoring of BP (S-MON, n = 51), (3) 
self-monitoring of BP plus guided management of anti-
hypertensive medications (S-MAN, n = 51). A target BP 
of ≤ 130/80 mmHg was used for office measurement, adjusted 
downwards to 120/75 mmHg for out-of-office measurement 
in the intervention groups (S-MON, S-MAN). This was to 
counteract the so-called ‘white coat’ effect of BP measure-
ment [8]. Daytime ambulatory BP monitoring values were 
used to provide BP measurements (study primary outcome) 
at baseline and 6-month follow-up. The intervention for both 
S-MON and S-MAN groups comprised self-monitoring over 
a 7-day period, taking two readings in the morning before 
treatment and two again about 12 h later using validated 
monitors at 6 weeks, 3 months and 5 months after baseline. 
Self-recorded values were passed to the general practitioner 
(GP) in the S-MON group by post/telephone and directly 
to the study team in the S-MAN group by telemetry, with 
a paper copy to the patient’s GP; the S-MAN group then 
received guidance from the study clinician regarding possible 
adjustments to their medications and jointly agreed on any 
changes without the need for a face-to-face appointment with 
their GP. Medication management in the TAU and S-MON 
groups was carried out by the GP with no input from the trial 
team. Data on changes in treatment, GP visits and adverse 
events were recorded at each study visit in TAU and S-MON 
at the beginning and end of the trial.
2.2  Health Economic Measurements and Analysis
Profiles as per the three-level EuroQoL-Five Dimensions 
(EQ-5D-3L) instrument were collected at baseline and 
6-month follow-up and converted to utilities using UK-
specific preference weights [9]. Quality-adjusted life-years 
(QALYs) over the follow-up period were then calculated 
as the area under the curve using linear interpolation 
between the two timepoints. Comparisons of QALYs 
between groups were adjusted for baseline utility [10].
Costs were calculated by extracting resource-use quan-
tities from the patient-completed resource-use question-
naires and multiplying them by unit costs taken from stand-
ard national health service (NHS) sources for 2017/18 [11, 
12]. Unit costs are reported in the online appendix. Where 
appropriate, costs were adjusted to year 2017/8 values using 
the hospital and community health services pay and prices 
index [13] (to 2016) and the new health services index [11]. 
Anti-hypertensive medication costs were calculated using 
frequency and dose of prescription alongside data on pack 
Key Points for Decision Makers 
On average, over a 6-month time horizon, self-manage-
ment of anti-hypertensive medication is not an efficient 
intervention. The incremental cost per 1 mmHg blood 
pressure (BP) reduction for self-monitoring of BP versus 
treatment as usual (TAU) was £137.
Point estimate quality-adjusted life-years (QALYs) 
accrued were very similar, although TAU had the highest 
point estimate.
As future cardiovascular events will be a major driver 
of QALYs, decision modelling is required to explore 
longer-term costs and outcomes.
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size and cost relevant for the NHS [14, 15]. To minimise 
respondent burden, a maximum of one medication per 
category (α-blockers, β-blockers, calcium channel block-
ers, diuretics, angiotensin-converting enzyme inhibitors or 
angiotensin-receptor blockers, and other anti-hypertensive 
medications) was recorded at baseline, 6 weeks, 3 months, 
and 5 months and at 6-month follow-up, with usage assumed 
constant between timepoints. The cost of the intervention 
included purchase price of the BP monitor and associated 
software costs, two nurse home visits incorporating time 
spent training patients in their use (nurse time and mileage 
costs applied) and telephone charges to remind patients to 
monitor their BP and to discuss treatment changes in the 
S-MON and S-MAN arms [11]. Prices for monitors and 
associated software (€, year 2012/3 values) were converted 
to ₤ at the historic rate (2012) of €1: ₤0.833, before being 
adjusted to year 2018 values. The economic evaluation was 
conducted from the perspective of the NHS over a time hori-
zon of 6 months (within-trial evaluation). No discounting 
was applied because of the short time horizon of the study. 
Data were analysed with Stata v16.0 (Stata Corp LLC, Col-
lege Station, TX, USA).
We report mean (95% confidence interval [CI]) change 
in SBP from baseline, QALYs accrued and cost per patient, 
with increments ± 95% CI reported compared with TAU. 
Primary analysis was based on as-treated groups; a sensitiv-
ity analysis was then carried out based on intention to treat 
(ITT). Point estimate incremental cost-effectiveness ratios 
(ICERs) are reported taking into account dominance and 
extended dominance, with uncertainty in the ICERs reported 
via cost-effectiveness acceptability curves (CEACs) and 
frontiers, showing the probability that each of the interven-
tions is the most cost effective at various thresholds of will-
ingness to pay (WTP) per point reduction in SBP. CEACs 
were calculated using 10,000 bootstrapped samples of the 
dataset. As the quantity of missing data was relatively low 
(approximately 10%; see Sect. 3), we report complete case 
analysis only (i.e. no adjustments for missing data).
3  Results
We excluded 14 participants (as-treated groups: one TAU, 
eight S-MON, five S-MAN) from the economic evaluation 
because their care resource-use data were incomplete. In 
total, 140 participants were analysed (51 TAU, 43 S-MON, 
46 S-MAN), with a further five patients (two TAU, two 
S-MON, one S-MAN) excluded from the QALY analysis 
because of missing utility data.
Table 1 shows the mean resource use and costs in each 
group, categorised by costs relating directly to the invention, 
primary/community care use, secondary care use and anti-
hypertensive medications. Mean overall costs were £473 for 
TAU, £853 for S-MON and £1035 for S-MAN. Differences 
were not statistically significant (all p ≥ 0.2).
Table 2 presents the key outcomes relating to the eco-
nomic evaluation. The incremental cost per additional 
1 mmHg SBP reduction with S-MON compared with TAU 
was £137. S-MON dominated S-MAN (i.e. on average, it 
was both more effective and less expensive). Figure 1 shows 
the net benefit for each randomised group over a range of 
WTP values per 1 mmHg SBP reduction, evaluated at the 
mean baseline SBP. This suggests that TAU is the preferred 
approach at WTP values < £137 for 1 mmHg SBP reduction; 
at higher values, S-MON is the preferred approach. Figure 2 
shows the corresponding CEACs. For the ITT analysis, 
S-MON had the highest probability of cost effectiveness as 
long as the WTP for a 1 mmHg SBP reduction was > £196. 
For the analysis based on QALYs, TAU dominated both the 
S-MON and the S-MAN treatment strategies. Figures 3 and 
4 show the net benefit and CEAC plots, respectively, cor-
responding to this analysis: TAU was the most cost-effective 
option, with very high certainty over this limited timeframe.
4  Discussion
In terms of BP reduction, on average, S-MON cost £137 
per 1 mmHg SBP reduction over 6 months compared with 
TAU. When taking an ITT approach, the ICER was £196 
per 1 mmHg SBP reduction. S-MAN was not an efficient 
option, yielding poorer outcomes and higher costs than 
S-MON. This was mostly due to the increased intervention 
cost, but the higher point estimate cost of anti-hypertensives 
is worth noting: the S-MAN group tended to use larger doses 
of medication and more different agents than the S-MON 
group, but these did not result in better BP control (at least 
within the 6-month trial time horizon) [7]. When consider-
ing cost effectiveness in terms of QALYs, TAU dominated 
both S-MON and S-MAN because point estimate QALYs 
were lower than TAU. However, we urge caution in inter-
preting these results: QALY accruals will be driven much 
more strongly by future cardiovascular events, which can-
not be captured within a 6-month time horizon. Combining 
our results with longer-term prognoses may yield increased 
QALYs through reduced BP, but decision modelling is 
required to confirm or refute this.
TEST-BP was restricted to the post-stroke and TIA sub-
population, so may be expected to provide slightly different 
estimates of the cost effectiveness of these interventions than 
studies carried out in other populations. One randomised trial 
of self-monitoring of BP compared with usual care in the wider 
hypertensive population reported that self-monitoring was 
cheaper because of reduced medication costs [16]. However, in 
that study, the self-monitoring target BP was not adjusted down, 
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which may have influenced treatment costs. Furthermore, pri-
mary and secondary care costs were not included, and details 
on the methods used to compare costs between groups were not 
given. A systematic review of self-monitoring with telemoni-
toring by Omboni et al. [17], again in the wider hypertensive 
population, incorporated a cost-effectiveness analysis. Six stud-
ies were analysed, and the authors reported that the cost of self-
monitoring with telemonitoring was greater than that of usual 
care by around €660, with a cost per 1 mmHg SBP reduction 
of €406. However, there was substantial heterogeneity between 
the studies, with only three reporting on medical costs in addi-
tion to intervention costs, and a wide range of follow-up dura-
tions. Along with the difference in population studied, this 
likely accounts for the differences from our findings.
A key strength of our study was the use of ambulatory BP 
monitoring for the outcome measure, as opposed to clinic BP 
measurement used in other studies [18, 19], thus decreasing 
the influence of the natural variability in BP measurement 
and reducing the risk of measurement bias [20]. Another 
strength was the simultaneous comparison of two interven-
tion strategies, this being the first health economic evalua-
tion of guided self-management exclusively in a stroke/TIA 
population.
The major limitation of this study was that it only pro-
vided a short-term perspective on the benefits and costs asso-
ciated with these interventions, focusing on the impact on 
BP. Studies with durations > 24 months have shown that the 
benefits of BP self-monitoring in terms of control decreased 
with time [21]. However, even modest BP reductions may 
Table 1  Mean resource use and associated cost by group, over the 6-month follow-up period (for those not lost to follow-up)
Data are presented as mean ± standard deviation; costs are presented as £
GP general practitioner, NA not applicable, OT occupational therapist, S-MAN self-monitoring and guided self-management of anti-hypertensive 
medication, S-MON self-monitoring of blood pressure, TAU treatment as usual
Intervention TAU (N = 51) S-MON (N = 43) S-MAN (N = 46)
Contacts Cost Contacts Cost Contacts Cost
Total cost 0 185 379
Primary and community care
 GP—surgery 1.5 ± 1.4 56 ± 51 1.8 ± 2.4 67 ± 89 1.6 ± 2.4 59 ± 87
 GP—phone 0.02 ± 0.1 0.16 ± 1.13 0.2 ± 0.5 1.32 ± 4.30 0.1 ± 0.5 0.88 ± 3.90
 GP—home 0 NA 0 NA 0 0 ± 0
 Nurse—surgery 0.8 ± 0.9 9.15 ± 9.79 1.3 ± 4.1 14.13 ± 44.01 0.6 ± 1.6 6.60 ± 17.04
 Nurse—phone 0.02 ± 0.1 0.10 ± 0.70 0 NA 0 0 ± 0
 Nurse—home 0 NA 0.8 ± 4.6 9.08 ± 50.39 0 0 ± 0
 Health visitor—surgery 0 NA 0 NA 0 0 ± 0
 Health visitor—phone 0 NA 0 NA 0 0 ± 0
 Health visitor—home 0 NA 0 NA 0.1 ± 0.9 6.72 ± 45.60
 Physiotherapist—surgery 0.2 ± 1.4 12.13 ± 72.60 0.2 ± 1.0 9.59 ± 49.36 0.2 ± 1.5 11.21 ± 76.01
 Physiotherapist—phone 0 NA 0 NA 0 0 ± 0
 Physiotherapist—home 0 NA 0.05 ± 0.3 2.40 ± 15.72 0.2 ± 0.9 10.09 ± 48.14
 OT—surgery 0.3 ± 1.5 14.15 ± 77.21 0 NA 0 0 ± 0
 OT—phone 0 NA 0 NA 0 0 ± 0
 OT—home 0.02 ± 0.1 1.01 ± 7.22 0.05 ± 0.3 2.40 ± 15.72 0.02 ± 0.1 1.12 ± 7.60
 Other—surgery 0.3 ± 1.5 16.17 ± 76.11 0.07 ± 0.3 3.60 ± 17.41 0.2 ± 0.9 8.97 ± 46.50
 Other—phone 0 NA 0 NA 0 0 ± 0
 Other—home 0.04 ± 0.2 2.02 ± 10.11 0 NA 0 0 ± 0
 Total cost 111 ± 242 110 ± 157 104 ± 181
Secondary care
 Outpatient appointment 0.6 ± 1.4 76 ± 172 0.9 ± 1.6 108 ± 194 0.7 ± 2.3 90 ± 285
 Day-case procedure 0.1 ± 0.5 73 ± 340 0.07 ± 0.3 52 ± 191 0.1 ± 0.7 81 ± 547
 Inpatient admission 0.06 ± 0.2 195 ± 787 0.1 ± 0.4 385 ± 1294 0.1 ± 0.5 360 ± 1596
 Total cost 343 ± 948 544 ± 1458 530 ± 1919
Anti-hypertensive medication
 Total cost 19 ± 27 14 ± 19 21 ± 26
Grand total cost 473 ± 1045 853 ± 1458 1035 ± 1953
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translate into sizeable risk reductions in terms of secondary 
stroke prevention [1]. Therefore, the relatively small reduc-
tions observed in the TEST-BP trial may convert into larger 
benefits in the longer term. Health economic modelling work 
would be needed to formally assess the long-term cost effec-
tiveness of these interventions in patients with stroke or TIA, 
though this would necessarily require a range of assump-
tions regarding the conversion of reductions in short-term 
SBP into lifetime QALYs, as has been implemented in the 
Table 2  Key costs and outcomes results for economic evaluation
Data are presented as means (95% confidence interval), costs are presented in £ and reductions are presented in mmHg
ITT intent to treat, NA not applicable, QALY quality-adjusted life-year, SBP systolic blood pressure, S-MAN self-monitoring and guided self-
management of anti-hypertensive medication, S-MON self-monitoring of BP, TAU treatment as usual
a Adjusted for baseline SBP
b Compared with TAU, after adjustment for baseline SBP
c Willingness-to-pay value at which the incremental net benefit was 0
d Compared with S-MON
e Evaluated at mean baseline utility (0.847)
Costs and outcomes TAU S-MON S-MAN
Primary analysis: SBP N = 51 N = 43 N = 46
 Mean reduction in SBP 3.6 (0.2 to 7.0) 6.7 (3.1 to 10.4) 6.1 (2.6 to 9.7)
 Incremental reduction in  SBPa,b NA 2.8 (− 1.6 to 7.1) 2.7 (− 1.5 to 7.0)
 Mean total cost 473 (186 to 760) 853 (417 to 1289) 1035 (471 to 1599)
 Incremental  costb NA 380 (− 254 to 1013) 562 (− 61 to 1184)
 Incremental cost per 1 mmHg reduction in  SBPa,c NA 137b Dominatedd
Sensitivity analysis: ITT N = 49 N = 45 N = 46
 Mean reduction in SBP 3.3 (− 0.1 to 6.7) 6.9 (3.3 to 10.4) 6.1 (2.6 to 9.7)
 Incremental reduction in  SBPa,b NA 2.5 (− 1.9 to 6.9) 2.6 (− 1.7 to 6.9)
 Mean total cost 408 (222 to 776) 905 (450 to 1359) 1035 (585 to 1484)
 Incremental  costb NA 495 (− 135 to 1124) 625 (− 1 to 1250)
 Incremental cost per 1 mmHg reduction in  SBPa,c NA 196b 1113d
Secondary analysis: QALYs N = 49 N = 41 N = 45
 Mean  QALYse 0.427 0.422 0.423
 Cost per  QALYc,e NA Dominated Dominated
Fig. 1  Net benefit for a range of values of WTP per 1  mmHg SBP 
reduction, by randomised group. GBP Great British pounds, SBP sys-
tolic blood pressure, SMan self-monitoring and guided self-manage-
ment of anti-hypertensive medication, SMo self-monitoring of blood 
pressure, TAU treatment as usual, WTP willingness to pay
Fig. 2  Cost-effectiveness acceptability curves based on SBP reduc-
tion, by randomised group. GBP Great British pounds, SBP systolic 
blood pressure, SMan self-monitoring and guided self-management 
of anti-hypertensive medication, SMo self-monitoring of BP, TAU 
treatment as usual
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general hypertensive population [22]. It should be noted that 
studies of 12–24 months’ duration tend to report a sustained 
effect from self-monitoring, but other data suggest this may 
diminish over the longer term [21].
Another limitation of our analysis is potential overestima-
tion of the cost of BP monitors. A monitor is likely to last 
more than the 6-month time horizon of this study. However, 
amortising the purchase price over a longer period would 
not materially change our results: S-MAN would still be 
dominated by S-MON, and the ICER of S-MON versus TAU 
would be lower (more cost effective).
Finally, we reported per-protocol analyses as our pri-
mary analysis because this represents costs and outcomes 
for patients who actually completed the interventions, but 
this is of course at risk of bias. We therefore also reported 
the ITT analysis.
Despite the growing body of evidence demonstrating 
the effectiveness of self-monitoring BP in various popula-
tions, few studies have carried out economic evaluations 
of this approach to date. Kaambwa et al. [22] reported a 
long-term cost-effectiveness analysis of the TASMINH2 
trial, which examined the use of telemonitoring and self-
monitoring of BP measurements in patients with hyperten-
sion. This analysis suggested that lifetime cost effectiveness 
was around £1600 per QALY in men and £5000 per QALY 
in women based on a continued BP reduction of 6.4 mmHg 
and 4.4 mmHg, respectively.
5  Conclusions
Self-management of BP is unlikely to be cost effective. A 
self-monitoring strategy costs an extra £137 per 1 mmHg 
SBP decrease over a 6-month time horizon. Decision model-
ling is required to project these findings to a lifetime horizon 
to explore whether it may yield further benefits in terms of 
reduced stroke recurrence and other cardiovascular impacts.
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